Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB1 | P08183 | 13/20 | 0.47 |
| ▸ | ABCG2 | Q9UNQ0 | 11/20 | 0.47 |
| ▸ | RET | P07949 | 1/20 | 0.42 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | BACE1 | P56817 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5787695 | 1.00 | ABCB1 (0.47) | ABCB1ABCG2RETHTR2AACHE | |
| SCHEMBL5787208 | 0.92 | ABCB1 (0.44) | ABCB1ABCG2RETHTR2AACHE | |
| SCHEMBL5787213 | 0.92 | ABCB1 (0.44) | ABCB1ABCG2RETHTR2AACHE | |
| SCHEMBL5785864 | 0.92 | DRD3 (0.42) | ABCB1ABCG2HTR2A | |
| SCHEMBL5785869 | 0.92 | DRD3 (0.42) | ABCB1ABCG2HTR2A | |
| SCHEMBL5785452 | 0.92 | THRB (0.46) | ABCB1ABCG2 | |
| SCHEMBL5785456 | 0.92 | THRB (0.46) | ABCB1ABCG2 | |
| SCHEMBL5782825 | 0.89 | ABCB1 (0.48) | ABCB1ABCG2RETACHE | |
| SCHEMBL5782830 | 0.89 | ABCB1 (0.48) | ABCB1ABCG2RETACHE | |
| SCHEMBL5785786 | 0.89 | ABCB1 (0.48) | ABCB1ABCG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1212318-B1 | SUBSTITUTED INDOLINONES AS TYROSINE KINASE INHIBITORS | BOEHRINGER INGELHEIM PHARMA (DE) | 2006-01-25 | — | — | EP | disclosed |
| US-20050009898-A1 | New substituted indolinones, their manufacture and their use as medicaments | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2005-01-13 | — | — | US | disclosed |
| US-6794395-B1 | Substituted indolinones, their manufacture and their use as medicaments | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-09-21 | — | — | US | disclosed |
| EP-1212318-A1 | SUBSTITUTED INDOLINONES AS TYROSINE KINASE INHIBITORS | Boehringer Ingelheim Pharma KG (DE) | 2002-06-12 | — | — | EP | disclosed |
| WO-2001016130-A1 | SUBSTITUTED INDOLINONES AS TYROSINE KINASE INHIBITORS | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2001-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009898-A1 | New substituted indolinones, their manufacture and their use as medicaments | CCNE1, CDK1, CCNI | ABCB1 435/4885ABCG2 196/4885RET 154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.